$ENVB
Enveric Biosciences, Inc. Stock $envb

$envb Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010431 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.784M	$2.822M	$11.61M
YoY Change	0.59%	-70.71%	-41.53%
% of Gross Profit
Research & Development	$1.990M	$1.893M	$8.028M
YoY Change	1.6%	-24.05%	67.64%
% of Gross Profit
Depreciation & Amortization	$44.30K	$86.50K	$159.2K
YoY Change	-36.05%	-49.79%	-75.76%
% of Gross Profit
Operating Expenses	$1.990M	$4.802M	$8.028M
YoY Change	-58.51%	-60.96%	-68.26%
Operating Profit	-$4.861M		-$27.42M
YoY Change	1.35%		-57.58%
Interest Expense	$11.00	$1.622M	$5.249K
YoY Change	-100.27%	-31717.15%	-150.86%
% of Operating Profit
Other Income/Expense, Net	$183.2K	$469.7K	$7.458M
YoY Change	-33.63%	-67.0%	-9.07%
Pretax Income	-$4.678M	-$10.16M	-$19.96M
YoY Change	3.39%	-79.49%	-64.63%
Income Tax		-$1.486M	-$1.486M
% Of Pretax Income
Net Earnings	-$4.678M	-$8.802M	-$18.47M
YoY Change	3.39%	-79.1%	-62.29%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.31		-$13.00
Diluted Earnings Per Share	-$2.31	-$4.22	-$13.00
COMMON SHARES
Basic Shares Outstanding	2.078M shares	2.078M shares	1.446M shares
Diluted Shares Outstanding	2.078M shares		1.446M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.56M	$17.72M	$17.72M
YoY Change	-42.1%	2.12%	2.12%
Cash & Equivalents	$12.56M	$17.72M	$17.72M
Short-Term Investments
Other Short-Term Assets	$2.277M	$708.1K	$708.1K
YoY Change	134.54%	85.92%	85.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.84M	$18.43M	$18.43M
YoY Change	-34.53%	3.92%	3.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$638.9K	$677.5K	$741.3K
YoY Change	-31.16%	130.1%	57.48%
Goodwill	$337.5K
YoY Change
Intangibles		$379.7K
YoY Change		-94.52%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.013M	$1.121M	$1.121M
YoY Change	-89.35%	-87.52%	-87.52%
TOTAL ASSETS
Total Short-Term Assets	$14.84M	$18.43M	$18.43M
Total Long-Term Assets	$1.013M	$1.121M	$1.121M
Total Assets	$15.85M	$19.55M	$19.55M
YoY Change	-50.74%	-26.82%	-26.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.793M	$463.3K	$463.3K
YoY Change	47.17%	-32.21%	-32.21%
Accrued Expenses	$1.028M	$1.706M	$1.769M
YoY Change	17.48%	31.94%	26.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$4.438M	$3.996M	$3.996M
YoY Change	112.0%	91.79%	91.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00		$0.00
YoY Change	-100.0%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.438M	$3.996M	$3.996M
Total Long-Term Liabilities	$0.00		$0.00
Total Liabilities	$5.447M	$3.996M	$4.881M
YoY Change	-29.61%	-9.45%	10.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$83.89M	-$79.21M
YoY Change		30.41%
Common Stock	$20.78K	$20.78K
YoY Change		218.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.41M	$14.67M	$14.67M
YoY Change
Total Liabilities & Shareholders Equity	$15.85M	$19.55M	$19.55M
YoY Change	-50.74%	-26.82%	-26.82%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.678M	-$8.802M	-$18.47M
YoY Change	3.39%	-79.1%	-62.29%
Depreciation, Depletion And Amortization	$44.30K	$86.50K	$159.2K
YoY Change	-36.05%	-49.79%	-75.76%
Cash From Operating Activities	-$5.137M	-$3.462M	-$17.15M
YoY Change	12.93%	-14.88%	49.65%
INVESTING ACTIVITIES
Capital Expenditures	$5.169K	$6.200K	$584.2K
YoY Change	-101.02%	-100.72%	-167.56%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$5.169K	-$6.200K	-$584.2K
YoY Change	-98.98%	-96.73%	-126.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$17.22M
YoY Change			-30.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$18.18M
YoY Change		-100.0%	-26.99%
NET CHANGE
Cash From Operating Activities	-$5.137M	-3.462M	-$17.15M
Cash From Investing Activities	-$5.169K	-6.200K	-$584.2K
Cash From Financing Activities		0.000	$18.18M
Net Change In Cash	-$5.162M	-3.468M	$367.9K
YoY Change	-218.85%	-18.53%	-97.65%
FREE CASH FLOW
Cash From Operating Activities	-$5.137M	-$3.462M	-$17.15M
Capital Expenditures	$5.169K	$6.200K	$584.2K
Free Cash Flow	-$5.142M	-$3.468M	-$17.73M
YoY Change	27.17%	8.3%	67.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000890821
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	ENVB	Inducement Expense InducementExpense		usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2021	ENVB	Stock Issued During Period Value Issued Pursuant Exercise Of Warrant StockIssuedDuringPeriodValueIssuedPursuantExerciseOfWarrant		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	ENVB	Redeemable Noncontrolling Interest Embedded Derivative And Net Of Issuance Costs RedeemableNoncontrollingInterestEmbeddedDerivativeAndNetOfIssuanceCosts		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	ENVB	Issuance Of Rounded Shares As Result Of Reverse Stock Split IssuanceOfRoundedSharesAsResultOfReverseStockSplit		usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	ENVB	Inducement Expense InducementExpense		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance		usd
CY2021	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise		usd
CY2021	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable		usd
CY2021	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative		usd
CY2021	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest		usd
CY2021	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	ENVB	Deferred Tax Liability Incurred Due To Amalgamation DeferredTaxLiabilityIncurredDueToAmalgamation		usd
CY2022	ENVB	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2022	ENVB	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2020Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill		usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022Q4	ENVB	Deferred Tax Accrued Bonus DeferredTaxAccruedBonus		usd
CY2021Q4	ENVB	Research And Development Capitalized Expenses ResearchAndDevelopmentCapitalizedExpenses		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses		pure
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38286
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENVERIC BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4484725
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4851 Tamiami Trail N
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34103
CY2022	dei	City Area Code CityAreaCode	(239)
CY2022	dei	Local Phone Number LocalPhoneNumber	302-1707
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2022	dei	Trading Symbol TradingSymbol	ENVB
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	11000000.0	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2078271	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2021	dei	Auditor Firm AuditorFirmId	711
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2021	dei	Auditor Name AuditorName	Friedman LLP
CY2021	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2022Q4	us-gaap	Cash Cash	17723884	usd
CY2021Q4	us-gaap	Cash Cash	17355999	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	708053	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	380838	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	18431937	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	17736837	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	677485	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294430	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63817	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	176304	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	379686	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6923928	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1587634	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1120988	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	8982296	usd
CY2022Q4	us-gaap	Assets Assets	19552925	usd
CY2021Q4	us-gaap	Assets Assets	26719133	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	463275	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	683393	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1705655	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1292721	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63820	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107442	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	851008	usd
CY2022Q4	ENVB	Warrant Liabilities Current WarrantLiabilitiesCurrent	185215	usd
CY2021Q4	ENVB	Warrant Liabilities Current WarrantLiabilitiesCurrent	653674	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	727000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3995973	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2737230	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	68861	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1607122	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1675983	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3995973	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4413213	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	885028	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	885028	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2078271	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2078271	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	651921	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	651921	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20782	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6519	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94395662	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83066656	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79207786	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60736453	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-536734	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30802	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14671924	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19552925	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26719133	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11605761	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20499052	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8027773	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4788807	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	7453662	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	38678918	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	327910	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	656643	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	27415106	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	64623420	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27415106	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-64623420	usd
CY2021	ENVB	Inducement Expense InducementExpense	1125291	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4315236	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9327326	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48976896	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	3472726	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-325000	usd
CY2022	us-gaap	Interest Expense InterestExpense	5249	usd
CY2021	us-gaap	Interest Expense InterestExpense	10316	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7457713	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8191719	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19957393	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56431701	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1486060	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7454805	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18471333	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48976896	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	33014	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	295976	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18800323	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48976896	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-505932	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	150475	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19306255	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48826421	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-103.69
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1446007	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	472343	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3415641	usd
CY2021	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost One StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCostOne	4617087	usd
CY2021	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost Two StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCostTwo	7016401	usd
CY2021	ENVB	Consideration Paid Pursuant To Amalgamation Agreement ConsiderationPaidPursuantToAmalgamationAgreement	39042282	usd
CY2021	ENVB	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3285171	usd
CY2021	ENVB	Stock Issued During Period Value Induced Conversion Of Stock Options Into Restricted Stock Awards StockIssuedDuringPeriodValueInducedConversionOfStockOptionsIntoRestrictedStockAwards	1125291	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12597001	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	33467	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	150475	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	150475	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48976896	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2022	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost Three StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCostThree	5802464	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2620671	usd
CY2022	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative	402000	usd
CY2022	ENVB	Redeemable Noncontrolling Interest Issuance Costs RedeemableNoncontrollingInterestIssuanceCosts	41962	usd
CY2022	ENVB	Issuance Of Redeemable Noncontrolling Series Preferred Stock IssuanceOfRedeemableNoncontrollingSeriesPreferredStock	-527	usd
CY2022	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	33014	usd
CY2022	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	295976	usd
CY2022	ENVB	Registered Direct Offering Pipe Offering Modification Of Warrants And Exercise Of Prefunded Warrants Net Of Offering Costs RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts	3249124	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	527	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-505932	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18471333	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14671924	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18471333	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4315236	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9327326	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	3472726	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-325000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2620671	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12597001	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	33467	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	7453662	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	38678918	usd
CY2022	ENVB	Noncash Income Tax Expense NoncashIncomeTaxExpense	-1504302	usd
CY2021	ENVB	Noncash Income Tax Expense NoncashIncomeTaxExpense	-7454805	usd
CY2021	ENVB	Inducement Expense InducementExpense	1125291	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	107291	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	24969	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	168750	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	643333	usd
CY2022	us-gaap	Depreciation Depreciation	159160	usd
CY2021	us-gaap	Depreciation Depreciation	13310	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	374058	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-826837	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	263686	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	383199	usd
CY2022	ENVB	Increase Decrease In Right Of Use Operating Lease Liability IncreaseDecreaseInRightOfUseOperatingLeaseLiability	-107288	usd
CY2021	ENVB	Increase Decrease In Right Of Use Operating Lease Liability IncreaseDecreaseInRightOfUseOperatingLeaseLiability	-24969	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17146723	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11457671	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	584165	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189719	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	675000	usd
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	3055328	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-584165	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2190609	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17222099	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21614488	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	958038	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3285171	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18180137	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24899659	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-81364	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	144942	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	367885	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15777539	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17355999	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1578460	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17723884	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17355999	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5249	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10316	usd
CY2022	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance	4323734	usd
CY2022	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise	251357	usd
CY2022	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable	3595420	usd
CY2022	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative	402000	usd
CY2022	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	33014	usd
CY2022	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	295976	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	39042282	usd
CY2021	ENVB	Deferred Tax Liability Incurred Due To Amalgamation DeferredTaxLiabilityIncurredDueToAmalgamation	9061927	usd
CY2021	ENVB	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	32754	usd
CY2021	ENVB	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	9981000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	201653	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zhoVbRbwfEI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_82A_za93CoRI88E8">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc. (“Enveric Biosciences, Inc.” “Enveric” or the “Company”) is a pharmaceutical company developing innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida. The Company has the following wholly owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Ltd. (“HoldCo”), MagicMed Industries, Inc. (“MagicMed”), and Enveric Canada. The Company has an Amalgamation Agreement (“Amalgamation Agreement”) and tender agreement (“Tender Agreement”) with Jay Pharma, which were entered into in prior years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2021, the Company entered into an Amalgamation Agreement (the “Amalgamation Agreement”) with 1306432 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (“HoldCo”), 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo (“Purchaser”), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (“MagicMed”), pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation (as defined herein), the amalgamated corporation (“Amalco”) will be an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September 16, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed Industries develops and commercializes psychedelic-derived pharmaceutical candidates. MagicMed’s psychedelic derivatives library, the Psybrary™, is an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Akos Spin-Off</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2022, the Company announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences, Inc. (formerly known as Acanna Therapeutics, Inc.), a majority owned subsidiary of the Company (hereafter referred to as “Akos”), which was incorporated on April 13, 2022, by way of dividend to Enveric shareholders (the “Spin-Off”). The Spin-Off will be subject to various conditions, including Akos meeting the qualifications for listing on the Nasdaq Stock Market, and if successful, would result in two standalone public companies. The new company as a result of the Spin-Off will be referred to as Akos. If the Spin-Off does not occur, the Company has guaranteed the redeemable non-controlling interest (“RNCI”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2022, the Company and Akos entered into a Securities Purchase Agreement (the “Akos Purchase Agreement”) with an accredited investor (the “Akos Investor”), pursuant to which Akos agreed to sell to the Akos Investor up to an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z9yyoJT1mkec" title="Sale of stock">5,000</span> shares of Akos’ Series A Convertible Preferred Stock (the “Akos Series A Preferred Stock”), par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zbWlFSydXe63" title="Preferred stock par value">0.01</span> per share at a price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zlH6o6AgucBa" title="Sale of stock price per share">1,000</span> per share, and warrants (the “Akos Warrants”) to purchase shares of Akos’ common stock (the “Akos Common Stock”), par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zMevxTYWdIw9" title="Common stock par value">0.01</span> per share, for an aggregate purchase price of up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zwmiCEKbKgp" title="Sale of stock, value">5,000,000</span> (the “Akos Private Placement”). Pursuant to the Akos Purchase Agreement, Akos has issued <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zo09HLCpHvrb" title="Sale of stock">1,000</span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsvKt4ALXEXb" title="Sale of stock, value">1,000,000</span> on May 5, 2022 (See Note 8).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse Stock Split</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2022 the Company affected a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20220713__20220714_ziFE2uy9jt0j" title="Reverse stock split">1-for-50 reverse stock split</span>. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern, Liquidity and Other Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zSqTX9pHrJ1b" title="Accumulated deficit">79,207,786</span> as of December 31, 2022 and further losses are anticipated in the development of its business. Further, the Company has operating cash outflows of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20220101__20221231_z5JdwXqSOhud" title="Net cash used in operating activities">17,146,723</span> for the year ended December 31, 2022. For the year ended December 31, 2022, the Company had a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_di_c20220101__20221231_zkHZdn8GeFed" title="Loss from operations">27,415,106</span>. Since inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of debt and equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2022, the Company had cash of $<span id="xdx_906_eus-gaap--Cash_iI_c20221231_zUnP62jJTlr3" title="Cash">17,723,884</span> and working capital of $<span id="xdx_909_ecustom--WorkingCapital_iI_c20221231_zJnD4WhviGbj" title="Working capital">14,435,964</span>. The Company’s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing of this Annual Report on Form 10-K. The Company believes that it has adequate cash on hand to cover anticipated outlays through December 31, 2023. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, which may include collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date of the financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation Risks</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The current inflationary trend existing in the North American economic environment is considered by the Company to be reasonably likely to have a material unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price inflation have caused a general increase the cost of labor and materials. In addition, there is an increased risk of the Company experiencing labor shortages as a result of a potential inability to attract and retain human resources due to increased labor costs resulting from the current inflationary environment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Developments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq Notice</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2022, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between January 5, 2022, through February 17, 2022, the Company did not meet the minimum bid price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20220218__srt--RangeAxis__srt--MinimumMember_zN4jQq4G8Lej" title="Share price">1.00</span> per share required for continued listing on the Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until August 17, 2022 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 29, 2022, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that for the last ten consecutive business days, from July 15 to July 28, 2022, the closing bid price of the Company’s common stock had been at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20220719__srt--RangeAxis__srt--MinimumMember_z1RkI298GeHl" title="Share price">1.00</span> per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50 reverse stock split
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79207786	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17146723	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27415106	usd
CY2022Q4	us-gaap	Cash Cash	17723884	usd
CY2022Q4	ENVB	Working Capital WorkingCapital	14435964	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z2UVkJQsZlF5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassification</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zpDmoHbe2Cp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z5t6WSjWGxuj">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock and the valuation of stock-based compensation, accruals associated with third party providers supporting research and development efforts, estimated fair values of long lives assets used to record impairment charges related to intangible assets, acquired in-process research and development (“IPR&D”), and goodwill, and allocation of purchase price in business acquisitions. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zEAxH77elQH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zcOnrAw1d2K2">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20221231__srt--StatementGeographicalAxis__country--US_zak9MR9vOij5">250,000</span> in the United States and $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20221231__srt--StatementGeographicalAxis__country--CA_zLf4hz5mu97b">100,000</span> in Canada. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. As of December 31, 2022, the Company had greater than $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20221231__srt--StatementGeographicalAxis__country--US_z1SdXneqoQ3e">250,000</span> and $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20221231__srt--StatementGeographicalAxis__country--CA_z3P0kd91rkc6" title="Cash FDIC insured amount">100,000</span> at US and Canadian financial institutions, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1901045	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	338695	shares
CY2021Q2	ENVB	Shares Issue And Outstanding Percentage SharesIssueAndOutstandingPercentage	0.366	pure
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000	usd
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	9834855	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8225862	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-21359	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1587634	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1486060	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-101574	usd
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	35500000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	29048164	usd
CY2021	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-76344	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	6375492	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5967602	usd
CY2022	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-407890	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1817721	usd
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	675000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	643333	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	-1404892	usd
CY2021	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	103940	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	548436	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	168750	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	379686	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1486060	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8225862	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5967602	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	29048164	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	-0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	-1404892	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	168750	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	643333	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	295314	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	126564	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	9711922	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	8225862	usd
CY2022	ENVB	Agreegate Impairment Of Intangible Assets Indefinitelived AgreegateImpairmentOfIntangibleAssetsIndefinitelived	35015766	usd
CY2021	ENVB	Agreegate Impairment Of Intangible Assets Indefinitelived AgreegateImpairmentOfIntangibleAssetsIndefinitelived	29048164	usd
CY2022Q4	ENVB	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	1404892	usd
CY2021Q4	ENVB	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	1404892	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	168750	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	168750	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	42186	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	379686	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	178775	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27345	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	677485	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294430	usd
CY2022	us-gaap	Depreciation Depreciation	159160	usd
CY2021	us-gaap	Depreciation Depreciation	13310	usd
CY2022Q4	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	195104	usd
CY2021Q4	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	224536	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1175963	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	594784	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	83255	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	335401	usd
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	251333	usd
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	138000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1705655	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1292721	usd
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of the Company’s common stock are entitled to one vote per share.
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021	ENVB	Inducement Expense InducementExpense	1125291	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) increase the aggregate number of shares available for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an “evergreen” provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of Common Stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company’s Common Stock authorized for issuance under the Incentive Plan will equal the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company’s Common Stock outstanding as of such issuance date. The Plan Amendment was approved by the Company’s stockholders at a special meeting of the Company’s stockholders held on July 14, 2022.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18596	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	76.50
CY2020Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	125.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2537245	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2482	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	149.00
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue	116.00
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Option Acquisitions In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionAcquisitionsInPeriodGross	19477	shares
CY2021	ENVB	Share Based Compensation Arrangements By Share Based Payment Award Options Acquisitions In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquisitionsInPeriodWeightedAverageExercisePrice	67.00
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Acquisitions Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcquisitionsWeightedAverageGrantDateFairValue	92.00
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2876	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.50
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	284.50
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	13850	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	84.50
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	81.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23829	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.00
CY2021Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	103.50
CY2022	ENVB	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	34333	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.07
CY2022	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue	2.58
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	175.00
CY2022	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Forfeited Or Cancelled Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue	140.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	48329	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.05
CY2022Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	44.82
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20774	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	74.65
CY2022Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	100.49
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M12D
CY2022	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised	0	shares
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised	2876	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	0	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2685	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice	3.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.12	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2416266	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12304514	usd
CY2020Q4	ENVB	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested	8923797	usd
CY2021	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged	-15363	shares
CY2021Q4	ENVB	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested	801024	usd
CY2022Q4	ENVB	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested	5514	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	4434	shares
CY2021Q4	ENVB	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	2188	shares
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4434	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	2188	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	19464	shares
CY2021	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	13176	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	233.00
CY2021	ENVB	Inducement Expenses InducementExpenses	826577	usd
CY2022	ENVB	Redeemable Noncontrolling Interest Embedded Derivative RedeemableNoncontrollingInterestEmbeddedDerivative	402000	usd
CY2022	ENVB	Redeemable Noncontrolling Interest Issuance Costs RedeemableNoncontrollingInterestIssuanceCosts	41962	usd
CY2022	ENVB	Redeemable Noncontrolling Interest Embedded Derivative And Net Of Issuance Costs Shares RedeemableNoncontrollingInterestEmbeddedDerivativeAndNetOfIssuanceCostsShares	556038	shares
CY2022	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	33014	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	295976	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	885028	usd
CY2022	ENVB	License Agreement Description LicenseAgreementDescription	Jay Pharma, Tikkun Olam LLC (“TO LLC”) and Tikkun Olam Hemp LLC (“TOH”) entered into a license agreement dated on January 10, 2020, pursuant to which Jay Pharma would acquire certain in-licensed and owned intellectual property rights related to the cannabis products in the United States (presently excluding the state of New York) from TO LLC and TOH, each of which is an affiliate of TO Holdings Group LLC, in exchange for royalty payments of (i) four percent (4.0%) of net sales of OTC cancer products made via consumer channels; and (ii) five percent (5.0%) of net sales of beauty products made via consumer channels; and (iii) three percent (3.0%) of net sales of OTC cancer products made via professional channels, along with a minimum net royalty payment starting in January 1, 2022 and progressively increasing up to a cap of $400,000 maximum each year for the first 10 years, then $600,000 maximum each year for the next 5 years, and an annual maximum cap of $750,000 each year thereafter during the term of the agreement
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63817	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	176304	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63817	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	176304	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63820	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107442	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	68861	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63820	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	176303	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	120667	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	30586	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64235	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	64235	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	415	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	63820	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P0Y7M6D
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y7M6D
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.120	pure
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.120	pure
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7251228	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15420364	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12706165	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41011337	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19957393	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56431701	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1486060	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7454805	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1486060	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	7454805	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1486060	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7454805	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8927330	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5509522	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1348928	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	858791	usd
CY2021Q4	ENVB	Deferred Tax Accrued Bonus DeferredTaxAccruedBonus	121051	usd
CY2022Q4	ENVB	Research And Development Capitalized Expenses ResearchAndDevelopmentCapitalizedExpenses	614041	usd
CY2022Q4	ENVB	Deferred Tax Assets And Intangible Amortization DeferredTaxAssetsAndIntangibleAmortization	54141	usd
CY2021Q4	ENVB	Deferred Tax Assets And Intangible Amortization DeferredTaxAssetsAndIntangibleAmortization	23204	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	33453	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35456	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10977893	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6548024	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1607122	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1607122	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	18349753	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	9411533	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16892754	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8664242	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	16377435	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	11911845	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	expire in 2030
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.026	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.031	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.040	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.043	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depreciation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation	-0.040	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depreciation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation	0.014	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.233	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.070	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.074	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.133	pure
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9061927	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	1607122	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4429869	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5207872	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	2684319	usd

Files In Submission

Name	View Source	Status
0001493152-23-010431-index-headers.html	Edgar Link	pending
0001493152-23-010431-index.html	Edgar Link	pending
0001493152-23-010431.txt	Edgar Link	pending
0001493152-23-010431-xbrl.zip	Edgar Link	pending
envb-20221231.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
envb-20221231_cal.xml	Edgar Link	unprocessable
envb-20221231_def.xml	Edgar Link	unprocessable
envb-20221231_lab.xml	Edgar Link	unprocessable
envb-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENVB
Enveric Biosciences, Inc. Stock $envb

2023 Q1 Form 10-K Financial Statement

#000149315223010431 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB Enveric Biosciences, Inc. Stock $envb

2023 Q1 Form 10-K Financial Statement

#000149315223010431 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB
Enveric Biosciences, Inc. Stock $envb